Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Tax Provisions: 2021-2025

Historic Tax Provisions for Apellis Pharmaceuticals (APLS) over the last 4 years, with Sep 2025 value amounting to $602,000.

  • Apellis Pharmaceuticals' Tax Provisions rose 0.33% to $602,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 27.04%. This contributed to the annual value of $1.2 million for FY2024, which is 45.50% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Tax Provisions stood at $602,000, which was up 20.40% from $500,000 recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Tax Provisions peaked at $1.4 million during Q4 2023, and registered a low of -$1.5 million during Q4 2022.
  • Over the past 3 years, Apellis Pharmaceuticals' median Tax Provisions value was $300,000 (recorded in 2023), while the average stood at $434,091.
  • In the last 5 years, Apellis Pharmaceuticals' Tax Provisions tumbled by 517.90% in 2022 and then spiked by 338.60% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Tax Provisions (Quarterly) stood at $352,000 in 2021, then tumbled by 517.90% to -$1.5 million in 2022, then spiked by 196.74% to $1.4 million in 2023, then tumbled by 81.59% to $262,000 in 2024, then rose by 0.33% to $602,000 in 2025.
  • Its last three reported values are $602,000 in Q3 2025, $500,000 for Q2 2025, and $341,000 during Q1 2025.